Zobrazeno 1 - 10
of 28
pro vyhledávání: '"I. A. Bokova"'
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 15, Iss 6, Pp 109-114 (2023)
A significant proportion of patients who have had COVID-19 continue to suffer from persistent symptoms such as severe weakness, shortness of breath, joint pain, mood swings and memory impairment during the recovery phase. More than half of the patien
Externí odkaz:
https://doaj.org/article/1608c1e303b4465d965dfcdd7a8afca4
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 15, Iss 6, Pp 128-134 (2023)
In preclinical and clinical studies, choline alfoscerate (CA) has proven to be highly effective in the correction of cognitive impairment (CI). The clinical effect of CA is seen in the improvement of mental activity, concentration, ability to remembe
Externí odkaz:
https://doaj.org/article/5480fa41e3bb4a449f38b5f581f4e845
Autor:
O. A. Shavlovskaya, О. А. Gromova, A. Yu. Kochish, Yu. D. Yukhnovskaya, I. D. Romanov, I. A. Bokova
Publikováno v:
Фармакоэкономика, Vol 16, Iss 3, Pp 482-499 (2023)
The review examines pharmacological agents that can have potential disease-modifying osteoarthritis drugs (DMOADs) status. DMOADs prevent the progression and further structural joint damage (structure-modifying effect), leading to a decrease in sympt
Externí odkaz:
https://doaj.org/article/25c7496b78894062b3703d4595d8f68f
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 15, Iss 4, Pp 105-111 (2023)
Understanding the major pathological pathways and the key molecules involved in the pathogenesis of inflammatory processes in joints, particularly in osteoarthritis (OA), is crucial for drug and pharmaconutraceuticals development. OA is a degenerativ
Externí odkaz:
https://doaj.org/article/27bf163886f1428a810a53cdb72a5d03
Autor:
O. A. Shavlovskaya, I. V. Sarvilina, O. A. Gromova, M. N. Sharov, I. A. Bokova, Y. S. Prokofieva, N. I. Shavlovskiy
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 14, Iss 4, Pp 87-95 (2022)
The article presents new views on the treatment of pain syndromes in musculoskeletal diseases, in particular in osteoarthritis (OA) of various localizations (gonarthrosis, coxarthrosis). New recommendations (2019–2020) of international societies fo
Externí odkaz:
https://doaj.org/article/48db463716584cfa83d6594c1047afd3
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 14, Iss 2, Pp 91-97 (2022)
The novel coronavirus infection is commonly referred to as COVID-19, sometimes by the name of the causative agent of a respiratory viral infection, as SARS-CoV-2. Frequently, the course of COVID-19 is divided into three main periods: acute COVID-19 (
Externí odkaz:
https://doaj.org/article/f4fb24ef89b54b8f94416ab97af11024
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 13, Iss 6, Pp 117-123 (2021)
More than 500 million people worldwide suffer from osteoarthritis (OA). Neck and low back pain (LBP) is one of the most common reasons for visiting a general practitioner to receive primary medical care in different countries. The prevalence of chron
Externí odkaz:
https://doaj.org/article/0f62e73b33ab405db97b8f070194520d
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 74-80 (2021)
Chronic pain continues to remain one of the urgent problems of modern medicine. From 15 to 25% of the adult population suffers from chronic pain. Medical treatment includes the appointment of non-steroidal anti-inflammatory drugs (NSAIDs) and muscle
Externí odkaz:
https://doaj.org/article/179c517afe43482ab6723deb23ffc9a1
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 209-215 (2021)
The issue nonsteroidal anti-inflammatory drugs (NSAIDs) use safety is associated with a high frequency of adverse events (AEs) from the gastrointestinal tract and cardiovascular risks. Patients with lower back pain (LBP) and osteoarthritis (OA), as a
Externí odkaz:
https://doaj.org/article/51b4b298d4074565b29c3ec9a03c63f3
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 52-59 (2021)
Tolperizone is a central type of muscle relaxant that is widely used in clinical practice for the treatment of patients with acute and chronic nonspecific lower back pain(LBP), inflammatory and degenerative-dystrophic joint diseases, and is used in t
Externí odkaz:
https://doaj.org/article/a751de3371864b7096f193edc7e515c8